| Cat. No. |
Product Name |
CAS No. |
Information |
| PC-60141 |
SGD-1882
|
1222490-34-7 |
SGD-1882 (PBD dimer, Pyrrolobenzodiazepine dimer) is a novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs).
|
| PC-60140 |
D211
|
1971075-99-6 |
A novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs); displays picomolar potency against AML cancer cell lines.
|
| PC-45714 |
Mertansine
|
139504-50-0 |
Mertansine (DM1) is a tubulin inhibitor; thiol-containing maytansinoid that create an antibody-drug conjugate (ADC); an ADC payload.
|
| PC-35367 |
SG3199
|
1595275-71-0 |
SG3199 (SG-3199) is a PBD dimer warhead component of antibody-drug conjugate (ADC) payload tesirine, demonstrates potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines with mean GI50 of 151.5 pM; high-efficiently causes DNA interstrand cross-links in cancer cells; ADCT-402 (loncastuximab tesirine) is a novel CD19-targeted ADC delivering SG3199, ADCT-402 is highly potent, dose-dependent antitumor activity in several subcutaneous and disseminated human tumor models with marked superiority to comparator ADCs delivering tubulin inhibitors. |
| PC-43367 |
Daunorubicin
|
20830-81-3 |
Daunorubicin is potent topoisomerase II (Topo II) inhibitor, interacts with DNA by intercalation and inhibition of macromolecular biosynthesis in cancer cells; Daunorubicin is a chemotherapy agent used to treat multiple cancer, secifically used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma; Daunorubicin and it's derivatives are widely used as payloads in antibody-drug conjugates (ADCs). Chemotherapeutic Agents Approved |
| PC-43366 |
Daunorubicin hydrochloride
|
23541-50-6 |
Daunorubicin is potent topoisomerase II (Topo II) inhibitor, interacts with DNA by intercalation and inhibition of macromolecular biosynthesis in cancer cells; Daunorubicin is a chemotherapy agent used to treat multiple cancer, secifically used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma; Daunorubicin and it's derivatives are widely used as payloads in antibody-drug conjugates (ADCs). Chemotherapeutic Agents Approved |
| PC-43365 |
Daun02
|
290304-24-4 |
Daun02 a prodrug that is converted by β-galactosidase to Daunorubicin, inactivate activated neurons that express both β-galactosidase and Fos, specifically attenuates cocaine-induced locomotor activity, also attenuates cocaine-induced β-galactosidase expression; daunorubicin, the active product of Daun02 metabolism by β-galactosidase, decreases the activity of MSNs in rat brain slices and that Daun02 strongly decreases the excitability of rat MSN primary cultures expressing β-galactosidase upon D1 dopamine receptor stimulation; Daun02-inactivation method, selectively inactivate only those neurons activated by cocaine in an environment repeatedly paired with drug injections. |
